Akili, a pioneer in therapeutic prescription digital medicine has closed successfully it’s $55 million financing Series C trial of medicine. This funding follows a successful trial, including study, developing and testing a novel digital medicine named AKL- T01. This flagship product of Akili aimed to treat a type of cognitive disorder- attention deficit/hyperactivity disorder (ADHD). Once approved and launched commercially, it would be the first digital and standalone therapeutic medicine for ADHD. Company’s other product in the pipeline and research, AKL-T02 will treat autism spectral disorder (ASD) or what simply known as autism.
Autism refers to another type of cognitive disorder, particularly in children, making them difficult to interact socially. The repetitive behavior and underdeveloped speech and verbal communication render them vulnerable in society. The reason behind autism could be genetic as well as environmental influence.
The above news has brought in a new ray of hope for an autism patient where there is no specific traditional medicine is available for its cure. This new development has the potential for treating this disorder, probably with more efficiency.
This funding will also help to advance products in the pipeline for treating multi sclerosis (MS) and depression. After approval by the U.S. Food and Drug Administration (FDA), it will be launched commercially for the patients. According to Akili AKL-T01 would be a standalone treatment for ADHD.
The company’s founder and CEO Eddie Martucci is quite happy with the response of investors and welcomed the financing. He said this financing indicates faith of people in his company’s potential in digital medicines and growth. According to him, the company will continue to grow and supply novel solutions in the redefined healthcare sector.
Akini Interactive is a company who believes in transforming healthcare through its digital therapeutics medicine solving Neuro-cognitive disorders. It believes in targeting specific cognitive area or nerve which has been suppressed by the dysfunction. The treatment includes, interestingly, not any pill, but customized action video games for patients to play.
Video games are designed by neuroscientists and entertainer engineered with algorithms to treat a cognitive disorder like depression. According to the company, highly-interactive and highly engaging games provide a therapeutic experience to patients which actually benefit them. Through high-end therapeutics interactive video games, the specific regions of the brain could become functional which has been suppressed by the disorder, improving the condition of the patient. There would second by second tracking of patient’s cognitive response and data available for any improvement in the patient’s condition.
AKL- T01 if approved by the FDA and then it would certainly indicate towards the acceptance of new healthcare solutions for patients. It has the capability to transform the whole healthcare process and system in coming years. This funding will boost the confidence of other investors, which are planning to invest or come together for such digital medicine research and development in the future and those patients who are searching for new areas to treat disorders like autism could be more than happy to read such positive …